ProPhase Labs, Inc. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- ProPhase Labs, Inc. payments for repurchase of common stock for the quarter ending 2024-12-31 was $0.00.
- ProPhase Labs, Inc. payments for repurchase of common stock for the quarter ending 2024-09-30 was $0.00.
- ProPhase Labs, Inc. payments for repurchase of common stock for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- ProPhase Labs, Inc. payments for repurchase of common stock for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- ProPhase Labs, Inc. payments for repurchase of common stock for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- ProPhase Labs, Inc. payments for repurchase of common stock for fiscal 2023 was $588.00K, a 72.68% decline from fiscal 2022.
- ProPhase Labs, Inc. payments for repurchase of common stock for fiscal 2022 was $2.15M, a 134.68% increase from fiscal 2021.
- ProPhase Labs, Inc. payments for repurchase of common stock for fiscal 2021 was $917.00K.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $0.00 10-K · filed 2025-04-01 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 derived: sum of 4 quarters · filed 2025-04-01 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $0.00 derived: sum of 4 quarters · filed 2025-04-01 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-10 | $47.00K derived: sum of 4 quarters · filed 2025-04-01 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $588.00K 10-K · filed 2025-04-01 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $1.54M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $47.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $1.59M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $541.00K 10-Q · filed 2024-05-10 | $1.54M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $952.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $2.15M 10-K · filed 2024-03-29 |
| 2022-09-30 | $50.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | |
| 2022-03-31 | $1.15M 10-Q · filed 2023-05-12 | |
| 2021-12-31 | $917.00K 10-K · filed 2023-03-29 | |
| 2017-12-31 | $4.48M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $16.28M 10-K · filed 2019-03-26 |
| 2017-09-30 | $9.94M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |